ASCO 2022 | The evolving standard of care for patients with metastatic hormone-sensitive prostate cancer

Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Victoria, Australia, talks on the evolution of the standard of care (SOC) for first-line treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Androgen deprivation therapy (ADT) has been SOC for almost a decade for this patient population. Although approximately 95% of men initially respond to ADT, the duration of response prior to the development of metastatic castration-resistant prostate cancer is relatively short, with a median time of 18 months. The addition of docetaxel to ADT saw an increase in benefit to mHSPC, and subsequently additional novel androgen-receptor targeted therapies, including abiraterone, enzalutamide and apalutamide, have been shown to advance treatment of mHSPC as doublet therapies. Recently, further progress has been made with triplet therapies, as seen in the Phase III PEACE-1 trial (NCT01957436) with ADT, docetaxel and abiraterone, and the Phase III ARASENS trial (NCT02799602) with the addition of darolutamide to ADT and docetaxel. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.